Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Agile Therapeutics Inc is a drug manufacturers-specialty & generic business based in the US. Agile Therapeutics shares (AGRX) are listed on the NASDAQ and all prices are listed in US Dollars. Agile Therapeutics employs 28 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.85|
|52-week range||$0.69 - $3.77|
|50-day moving average||$1.01|
|200-day moving average||$1.35|
|Wall St. target price||$3.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||7.82%|
|1 month (2021-09-20)||-15.90%|
|3 months (2021-07-23)||-26.78%|
|6 months (2021-04-23)||-53.33%|
|1 year (2020-10-22)||-71.78%|
|2 years (2019-10-22)||-28.62%|
|3 years (2018-10-22)||4.86%|
|5 years (2016-10-21)||7|
|Revenue TTM||$2.1 million|
|Gross profit TTM||$467,000|
|Return on assets TTM||-51.72%|
|Return on equity TTM||-128.85%|
|Market capitalisation||$90.9 million|
TTM: trailing 12 months
There are currently 2.5 million Agile Therapeutics shares held short by investors – that's known as Agile Therapeutics's "short interest". This figure is 1.1% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting Agile Therapeutics shares can be evaluated.
Agile Therapeutics's "short interest ratio" (SIR) is the quantity of Agile Therapeutics shares currently shorted divided by the average quantity of Agile Therapeutics shares traded daily (recently around 521219.66527197). Agile Therapeutics's SIR currently stands at 4.78. In other words for every 100,000 Agile Therapeutics shares traded daily on the market, roughly 4780 shares are currently held short.
However Agile Therapeutics's short interest can also be evaluated against the total number of Agile Therapeutics shares, or, against the total number of tradable Agile Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agile Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Agile Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0312% of the tradable shares (for every 100,000 tradable Agile Therapeutics shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Agile Therapeutics.
Find out more about how you can short Agile Therapeutics stock.
We're not expecting Agile Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Agile Therapeutics's shares have ranged in value from as little as $0.686 up to $3.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agile Therapeutics's is 1.0249. This would suggest that Agile Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Agile Therapeutics, Inc. , a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.